喉 dystonia 和声音震对注射肉毒素的反应
João Viana Pinto1, Isabel García López2
1Department of Otolaryngology Head & Neck Surgery, La Paz University Hospital, Madrid, Spain. joaopvfpinto@gmail.com.
概括
毒素 (BTX) 注射有效地改善了喉 dystonia (LD) 和声震 (VT) 的患者的语音质量. 与声震患者相比,喉 dystonia 患者对 BTX 治疗的反应更为显著.
科学领域:
- 神经学 神经学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 语音和语言病理学 语言病理学
背景情况:
- 喉 dystonia (LD) 和声震 (VT) 是常见的声音障碍.
- 毒素 (BTX) 注射是这些疾病的治疗选择之一.
- 将BTX在LD与VT中的疗效进行比较对于治疗优化至关重要.
研究的目的:
- 在患有喉 dystonia (LD) 和声震 (VT) 的患者中比较肉毒素 (BTX) 注射的治疗结果.
主要方法:
- 在77名患者 (44名LD,33名VT) 的回顾性研究中,从2010年到2022年通过电肌学治疗BTX.
- 通过使用语音障碍指数 (VHI-10),视觉模拟尺度 (VAS) 测定语音障碍等级,GRBAS (I) 尺度和最大声调时间 (MPT) 评估改善.
主要成果:
- 在BTX注射后,LD和VT两组都表现出显著的声音改善 (VHI-10,VAS和GRBAS (I) 评分下降).
- 在第一次注射后,喉 dystonia 患者在 VAS 和 GRBAS ((I) 尺度的"S" (菌株) 参数中表现出更大的改善.
- 接受多次注射的患者在LD组的G,S和I参数中表现出更明显的改善,与VT组相比.
结论:
- 毒素 (BTX) 注射在改善喉 dystonia (LD) 和声震 (VT) 的声音质量方面是有效的.
- 与声震相比,喉 dystonia 似乎对肉毒素治疗的反应优于声震.
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
654
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
654
Skeletal Muscle Relaxants: Therapeutic Uses
463
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
463
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Myasthenia Gravis: Diagnostic Tests
644
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
644
Skeletal Muscle Relaxants: Adverse Effects
335
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
335
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
391
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
391


